2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value:
As we indicated last month, the Board has commenced a process to consider all options to maximize value. This process is well underway and our team is committed to working as thoughtfully and quickly as possible to ensure our important therapies become available to patients in need, we drive value for our shareholders and best support our employees.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.